Esme Pelin, Botsali Aysenur, Akoglu Gulsen, Caliskan Ercan
Department of Dermatology and Venereology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
Skin Appendage Disord. 2022 Jul;8(4):342-345. doi: 10.1159/000521860. Epub 2022 Feb 9.
Although adalimumab is the only approved biologic for the treatment of hidradenitis suppurativa (HS), the treatment response may not be satisfactory in all patients. Recently, many other biological agents, including interleukin 17 inhibitors such as ixekizumab, have shown promise.
Five severe HS (Hurley stage III) patients resistant to conventional treatments and adalimumab for at least 3 months were recruited. Patients were prescribed ixekizumab with a scheme approved for psoriasis (160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12.) The primary outcome measure was achieving the Hidradenitis Suppurativa Clinical Response (HiSCR) score following 12 weeks. Secondary outcome measures included the patient-reported Dermatology Life Quality Index (DLQI) and visual analog scale (VAS). Four of 5 patients (80%) achieved HiSCR. While improvement was observed in the VAS and DLQI scores of 4 patients, the decline was limited in 1 patient. No adverse event was recorded related to ixekizumab.
The result of our observation suggests that ixekizumab may be effective for HS, especially in challenging cases.
尽管阿达木单抗是唯一被批准用于治疗化脓性汗腺炎（HS）的生物制剂，但并非所有患者的治疗反应都令人满意。最近，许多其他生物制剂，包括诸如司库奇尤单抗等白细胞介素17抑制剂，已显示出前景。
招募了5例对传统治疗和阿达木单抗耐药至少3个月的重度HS（Hurley III期）患者。患者按照批准用于银屑病的方案使用司库奇尤单抗（160 mg单次给药，随后在第2、4、6、8、10和12周各给药80 mg）。主要结局指标是12周后达到化脓性汗腺炎临床反应（HiSCR）评分。次要结局指标包括患者报告的皮肤病生活质量指数（DLQI）和视觉模拟量表（VAS）。5例患者中有4例（80%）达到HiSCR。虽然4例患者的VAS和DLQI评分有所改善，但1例患者的下降有限。未记录到与司库奇尤单抗相关的不良事件。
我们的观察结果表明，司库奇尤单抗可能对HS有效，尤其是在具有挑战性的病例中。
